High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of

deaths in urban Malawi

Marah G. Chibwana[1§], Khuzwayo C. Jere[1,2§], Raphael Kamn'gona[1], Jonathan Mandolo[1],

Vincent Katunga-Phiri[1], Dumizulu Tembo[1], Ndaona Mitole[1], Samantha Musasa[3], Simon

Sichone[1], Agness Lakudzala[1], Lusako Sibale[1], Prisca Matambo[1], Innocent Kadwala[1], Rachel

L. Byrne[4], Alice Mbewe[1], Marc Y. R. Henrion [1,4], Ben Morton[1,4], Chimota Phiri[5], Jane

Mallewa[3], Henry C Mwandumba[1,4], Emily R. Adams[4], Stephen B. Gordon[1,4]*, Kondwani C.

Jambo[1,4]*

[1] Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

[2] Centre for Global Vaccine Research, Institute of Infection, Veterinary Ecological Sciences,

University of Liverpool, Liverpool, UK.

[3] Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.

[4] Liverpool School of Tropical Medicine, L3 5QA, Liverpool, United Kingdom.

[5] Ministry of Health, Queen Elizabeth Central Hospital, Blantyre, Malawi

Corresponding author: Kondwani C. Jambo (kjambo@mlw.mw)

[§]Authors contributed equally.

*Joint senior authors

Key Words: SARS-CoV-2, COVID-19, Malawi, Seroprevalence, IgG

Abstract

Background: In low-income countries, like Malawi, important public health measures

including social distancing or a lockdown have been challenging to implement owing to

socioeconomic constraints, leading to predictions that the COVID-19 pandemic would

progress rapidly. However, due to limited capacity to test for severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) infection, there are no reliable estimates of the true

burden of infection and death. We, therefore, conducted a SARS-CoV-2 serosurvey amongst

health care workers (HCWs) in Blantyre city to estimate the cumulative incidence of SARS-

CoV-2 infection in urban Malawi.

Methods: We recruited 500 otherwise asymptomatic HCWs from Blantyre City (Malawi)

from 22nd May 2020 to 19th June 2020 and serum samples were collected from all

participants. A commercial ELISA was used to measure SARS-CoV-2 IgG antibodies in

serum.

Results: A total of 84 participants tested positive for SARS-CoV-2 antibodies. The HCWs

with positive SARS-CoV-2 antibody results came from different parts of the city. The

adjusted seroprevalence of SARS-CoV-2 antibodies was 12.3% [CI 8.2 - 16.5]. Using age-

stratified infection fatality estimates reported from elsewhere, we found that at the observed

adjusted seroprevalence, the number of predicted deaths was eight times the number of

reported deaths.

Conclusions: The high seroprevalence of SARS-CoV-2 antibodies among HCWs and the

discrepancy in the predicted versus reported deaths suggests that there was early exposure but

slow progression of COVID-19 epidemic in urban Malawi. This highlights the urgent need

for development of locally parameterised mathematical models to more accurately predict the

trajectory of the epidemic in sub-Saharan Africa for better evidence-based policy decisions

and public health response planning.

Introduction

Coronavirus disease 2019 (COVID-19) has had a dramatic impact worldwide, with high mortality in Asia, Europe and the Americas (1). Africa reported its first COVID-19 case on 14th February 2020 (2). Due to poor socio-economic conditions, high HIV prevalence, an increase in non-communicable diseases and challenged health system infrastructure, it was predicted that the African pandemic would progress rapidly. As of 16th July 2020, however, the number of COVID-19 cases was 665,522 and deaths 14,434 (1, 2), much lower than predicted by mathematical models (3).

In low-income countries, like Malawi, important public health measures like social distancing or a lockdown are difficult to implement owing to socioeconomic constraints. Furthermore, the limited capacity to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impedes effective public health response planning. Initial testing in Malawi focused on case identification in patients with COVID-19-like symptoms, contacts of index patients and inbound travellers. The first COVID-19 case in Malawi was reported on 2nd April and as of 16th July 2020 there were 2716 cases with only 51 deaths reported (2, 4). Given the sampling strategy, the true burden is certainly much greater than the reported cases, but there are no reliable estimates of the true burden of infection and death. Up to now, health services have reported only small number of cases and have not been overwhelmed as predicted (3).

The unrestricted nature of the COVID-19 epidemic in Malawi provides an opportunity to compare its trajectory in a low-income setting with what has been reported in high income settings. It has been shown that the rate of asymptomatic SARS-CoV-2 infection among health care workers (HCWs) reflects general community transmission rather than in-hospital exposure (5). We, therefore, conducted a SARS-CoV-2 serosurvey amongst HCWs in

Blantyre city to estimate the cumulative incidence of SARS-CoV-2 infection in urban

Malawi.

Methods

Ethical statement

Ethical approval was provided by the College of Medicine Research and Ethics Committee

(COMREC, Malawi) (P.05/20/3045) and Liverpool School of Tropical Medicine (LSTM,

UK) (20-043). All participants gave informed written consent.

Study setting and participants

Participant recruitment was done at the Malawi-Liverpool-Wellcome Trust Clinical Research

programme (MLW) in Blantyre, Malawi, as part of an ongoing longitudinal study that seeks

to investigate markers of SARS-CoV-2 exposure and immunological protection in Malawian

adults. The study site is within the compound of the Queen Elizabeth Central Hospital

(QECH), the largest tertiary teaching hospital in Malawi. It is easily accessible from most

parts of the city. Participants were HCWs from Blantyre City, both clinical and non-clinical.

We used a convenience sampling approach, whereby the study was advertised electronically

and by word of mouth. The sample size was calculated based on the study primary objective,

which was to compare the SARS CoV-2 neutralising antibody titers in recovered COVID-19

patients compared to SARS CoV-2 antibody positive (asymptomatic/mild) individuals.

Inclusion criteria for the study included being an HCW resident in Blantyre, aged between 18

and 65 years old, and otherwise symptomatic. The exclusion criterion was withholding

consent. Electronic case report forms (eCRFs) were used to collect demographic data

including age, gender, place of residence, common mode of transportation, occupation and

involvement in COVID-19 work. The samples used for this manuscript are from the baseline

recruitment arm of the asymptomatic group in the main study.

Sample collection, processing and experimental setup

Peripheral blood (10ml), 7ml in Sodium Heparin tubes and 3ml in serum separation tubes

(SST) (All BD Biosciences), was collected from all study participants using venesection by

the study clinical team at the study site (MLW) between 22nd May 2020 to 19th June 2020.

Serum was collected from the SSTs by centrifugation at 500g for 8 mins and stored at -80°C.

To measure SARS-CoV-2 antibodies, we used a commercial enzyme linked-immunosorbent

assay (ELISA) targeting Spike (S2) and Nucleoprotein (N) from SARS-CoV-2 (Omega

diagnostics, UK; ODL 150/10; Lot #103183). The assay was performed as per the

manufacturer's instructions. In brief, participant serum was diluted (1:200) in sample diluent

(150mM Tris-buffered saline, pH 7.2 with antimicrobial agent). The diluted samples, diluent

alone (negative control), manufacturer's cut-off control and positive control were added at

100μl per well. The plate was incubated at room temperature for 30 mins. After incubation,

the plate was washed three times with wash buffer (100mM Tris-buffered saline with

detergent, pH 7.2) using a plate washer (Asys Atlantis, Biochrom Ltd, UK). Human IgG

conjugated to horseradish peroxidase was then added to each well at 100μl and incubated for

30 minutes at room temperature. After incubation, the plate was washed four times with

wash buffer, and 100μl of TMB (3,3',5,5'-Tetramethylbenzidine) Substrate (aqueous solution

of TMB and hydrogen peroxide) was added. The plate was incubated for 10 minutes at room

temperature, before addition of 100μl of Stop Solution (0.25M sulphuric acid). The optical

density (OD) of each well was read at 450nm in a microplate reader (BioTek ELx808, UK)

within 10 minutes. The assay interpretation was as follows; positive result (OD 0.6),

indeterminate result (OD 0.55 to < 0.6) and negative (OD < 0.55) This assay has undergone

rigorous independent validation at the Liverpool School of Tropical Medicine (UK) and St

George's University of London (UK) (6).

Statistical analysis

Graphical presentation was performed using GraphPad Prism 8 (GraphPad Software, USA).

To integrate uncertainty arising from test sensitivity and specificity, we used a method

published by Reiczigel *et al,* 2010 (7). The geospatial data was plotted in R (v4.0.0) using

ggmap (v3.0.0) (8) and ggplot2 (v3.3.1) (9).

Results

Demographics of study participants

We recruited 500 asymptomatic HCWs with a median age of 31 (range 20-64 years). The

average household size for the participants was 4 [confidence interval (CI) 3–5]. Of the 500,

331 were clinical HCWs and 169 non-clinical HCWs (Table 1). The clinical HCWs included

nurses, medical doctors and clinical officers, while the non-clinical HCWs included

clerical/administration, field workers and laboratory scientists. The primary workstation for

the HCWs included primary healthcare facilities (35/500), secondary healthcare facilities

(291/500), and clinical research facilities (174/500). The majority of the participants were

nurses (57%), 41% of all participants were involved in clinical work related to COVID-19

and 73% of the total participants used public transport or walking as their main means of

transport. The main characteristics of the participants are summarised in Table 1.

Seroprevalence of SARS CoV-2 antibodies and geospatial location of the antibody positive

individuals

84 participants tested positive for SARS-CoV-2 antibodies (Figure 1). After adjusting for test

sensitivity and specificity (6, 7), the overall seroprevalence of SARS-CoV-2 antibodies was

12.3% [CI 8.2 - 16.5]. This suggests that local transmission was high and that SARS-CoV-2

may have been circulating for some time in Blantyre City.

To estimate the potential geographical spread of SARS-CoV-2, we plotted the geographical

coordinates of place of residence for the individuals with a positive antibody result on the

map of Blantyre City. We found that the HCWs with a positive SARS-CoV-2 antibody result

came from different parts of the city (Figure 2). This suggests that SARS-CoV-2 local

transmission was likely widespread across the city.

Crude projections of mortality based on seroprevalence estimates

Using estimates of infection fatality rates from Verity *et al.* (10) and the Malawi population

census (11), we estimated the number of deaths that could have occurred at the observed

seroprevalence of SARS-CoV-2 antibodies (Table 2). We adjusted the population estimates

by inflating them to take into account population annual population growth rate of 2% from

2018 to 2020 (11). We assumed that there was a uniform risk of infection at all age groups

and that the seroprevalence was similar to the general population.

The crude estimates suggest that there should have been at least 138 deaths by 19th June

2020. However, four weeks following the serosurvey, only 17 COVID-confirmed deaths in

Blantyre have been reported by the Public Health Institute of Malawi (4), which is

approximately eight times below the predicted deaths. When the seroprevalence is

extrapolated to the entire Malawi, it predicts approximately 5,295 COVID-19 deaths, but

only 51 deaths have been reported as of 16th July 2020. These crude estimates highlight a

discrepancy between the predicted deaths using infection fatality rates from elsewhere and

the actual number of reported COVID-19 deaths in Malawi.

Conclusions

To our knowledge, this seroprevalence study is the first to report estimates of SARS-CoV-2

exposure among HCWs in an African urban low-income setting. It provides insights into the

potentially unique trajectory of the COVID-19 epidemic in sub-Saharan Africa (SSA), using

data from urban Malawi. We observe a high seroprevalence of SARS-CoV-2 antibodies

amongst HCWs. It has been reported elsewhere that HCWs accounted for a high proportion

of cases early in the SARS-CoV-2 outbreak when transmission was increasing sharply and

personal protective equipment (PPE) provision was patchy (12-14). Our data could suggest

that Malawi is relatively early in the epidemic and that COVID-19 cases are likely to

continue to rise sharply in the coming weeks, but the serology also suggests that large

numbers of cases must be either asymptomatic or only show mild disease.

The discrepancy between the predicted compared to reported mortality at the observed

seroprevalence estimate may also suggest that there are large numbers of underreported or

misclassified deaths in Malawi. However, even in countries like South Africa with relatively

abundant testing capacity and strong health systems, there is relatively low mortality with a

case fatality ratio of 1.5 (15). This may imply that the impact of SARS-CoV-2 in Africa is

potentially much less severe or is following a different trajectory than that experienced in

China, Americas and Europe, where case fatality ratios were commonly above five (1). This

warrants further investigation.

However, the reasons behind the discrepancy in the COVID-19 pandemic trajectory between

SSA and elsewhere might include population demography, climate and prior cross-reactive

immunity (16). In Malawi, for example, the population is younger (median age 17 years old)

(11), and the elderly who mostly experience worse outcomes in other settings (10), are 5.1%

of the population (11), largely residing in rural areas. If the prevalence of SARS-CoV-2 is

very low in rural areas, this may explain the low number of deaths, and would strengthen the

call to shield the elderly (17).

This study has some limitations. First, selection bias is likely due to the convenience

sampling approach; however, targeting HCW for regular serosurveys could help predict local

transmission outbreaks. Second, this serosurvey focused on an urban population where

Malawi has reported the highest concentration of COVID-19 cases. The seroprevalence in the

rural population remains unknown, but if high, may prompt other explanations for the

African/Malawi situation. Third, current SARS-CoV-2 ELISAs are still undergoing rigorous

validation and verification in the African settings, hence seroprevalence estimates could

change with new information on the accuracy of the test kits.

In conclusion, our findings indicate a major discrepancy between predicted COVID-19

mortality at the observed SARS-CoV-2 seroprevalence in HCWs with reported COVID-19

deaths in urban Malawi. The high seroprevalence estimate implies earlier exposure of SARS-

CoV-2 than that reported but with slow progression of the COVID-19 epidemic.

Development of locally parameterised mathematical models should be prioritised to more

accurately predict the trajectory of the epidemic in SSA. This will allow better evidence-

based policy decision-making and public health response planning.

Data availability

Figshare: High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low

numbers of deaths in urban Malawi. https://doi.org/10.6084/m9.figshare.12745214.v2

This project contains the following underlying data:

- PROTECT_FigShare Part 1 31072020.csv

- PROTECT_screening_enrolment_data_dictionary Figshare 31072020.pdf

Data are available under the terms of the Creative Commons Attribution 4.0 International

license (CC-BY 4.0).

Acknowledgements

We acknowledge the PROTECT Study Team at the Malawi-Liverpool-Wellcome Trust

Clinical Research Programme, namely Alice Kalilani, Gift Sagawa, Martha Moyo, Orpha

Kumwenda, Sharon Nthala, Chisomo Jassi, Neema Nyakuleha and Tayamika Banda.

We thank Dr Joe Fitchett at Mologic (UK) for providing the SARS-CoV-2 ELISA kits and

Dr Peter McPherson (MLW/LSTM) for the epidemiological support.

Grant information

This work was funded by the Wellcome Trust through a Wellcome Training Fellowship

[201945; to K.C.J], the Wellcome Trust/DFID Joint Initiative for Research in Epidemic

Preparedness and Response [220764; to E.R.A] and the Malawi-Liverpool-Wellcome Trust

Clinical Research Programme [MLW] was supported by a strategic award from the

Wellcome Trust awarded to S.B.G. K.C.J was also supported by the NIHR and MRC through

grant numbers 3477609 and MR/T008822/1, respectively. M.G.C. is supported by NIH

through grant number U01AI131348. E.R.A is also supported by the NIHR HPRU [200907]

in Emerging and Zoonotic Infection..

Disclaimer

The funders had no role in the study design, data collection and interpretation, or the decision

to submit the work for publication. Mologic (UK) was provided the opportunity to review a

preliminary version of this manuscript for factual accuracy but the authors are solely

responsible for final content and interpretation. The authors received no financial support or

other form of compensation related to the development of the manuscript. The findings and

conclusions in this report are those of the authors.

Competing interests

E.R.A. and R.L.B. worked with Mologic (UK) to independently validate the SARS-CoV-2

ELISA at the Liverpool School of Tropical Medicine (LSTM). All other authors report no

potential conflicts.

References

1. JHU. COVID-19 Case Tracker 2020 [cited; Available from:

https://coronavirus.jhu.edu/map.html.

2. CDC A. Latest updates on the COVID-19 crisis from Africa CDC. 2020 [cited 2020

15.07.2020]; Available from:

3. Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The

impact of COVID-19 and strategies for mitigation and suppression in low- and middle-

income countries. Science. 2020 Jun 12.

4. PHIM. Daily COVID--19 Situation Report. Lilongwe: Public Health Institute of

Malawi, Ministry of Health; 2020 1st July 2020.

5. Treibel TA, Manisty C, Burton M, McKnight A, Lambourne J, Augusto JB, et al.

COVID-19: PCR screening of asymptomatic health-care workers at London hospital.

Lancet. 2020 May 23;395(10237):1608-10.

6. Adams ER, Augustin Y, Byrne RL, Clark DJ, Cocozza M, Cubas-Atienzar AI, et al.

Rapid development of COVID-19 rapid diagnostics for low resource settings:

accelerating delivery through transparency, responsiveness, and open collaboration.

medRxiv. 2020.

7. Reiczigel J, Földi J, Ozsvári L. Exact confidence limits for prevalence of a disease

with an imperfect diagnostic test. Epidemiology and infection. 2010 Nov;138(11):1674-

8.

8. Kahle D, Wickham H. ggmap: Spatial Visualization with ggplot2. The R Journal

2013;5(1):144-61.

9. Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New

York; 2016.

10.   Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of

the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis.

2020 Jun;20(6):669-77.

11.   NSO. 2018 Malawi Population and Housing. Zomba: National Statistical Office,

Government of Malawi; 2019.

12.   Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, et al. Coronavirus Disease 2019

(COVID-2019) Infection Among Health Care Workers and Implications for Prevention

Measures in a Tertiary Hospital in Wuhan, China. JAMA network open. 2020 May

1;3(5):e209666.

13.   Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, Bentvelsen RG, van den

Bijllaardt W, van Oudheusden AJG, et al. Prevalence and Clinical Presentation of Health

Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During

an Early Phase of the Pandemic. JAMA network open. 2020 May 1;3(5):e209673.

14.   Cheng VC, Wong SC, Yuen KY. Estimating Coronavirus Disease 2019 Infection

Risk in Health Care Workers. JAMA network open. 2020 May 1;3(5):e209687.

15.   Government SA. Update on Covid-19.   2020   [cited; Available from:

https://sacoronavirus.co.za

16.   Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is There

Low Morbidity and Mortality of COVID-19 in Africa? The American journal of tropical

medicine and hygiene. 2020 Jun 1.

17.   Divala T, Burke RM, Ndeketa L, Corbett EL, MacPherson P. Africa faces difficult

choices in responding to COVID-19. Lancet. 2020 May 23;395(10237):1611.

Figure Legends

Figure 1. SARS-CoV-2 serological results from asymptomatic health care workers. We

used a commercial ELISA to measure SARS-CoV-2 antibodies against Spike (S2) and

Nucleoprotein (N). OD, optical density.

Figure 2. Map of Blantyre showing geospatial distribution of seropositive results. We

collected geocoordinate data for the place of residence of all study participants at recruitment.

The geocoordinates were combined with the ELISA assay results and plotted on the map of

Blantyre using R. Black dot, seronegative; Orange dot, indeterminate; Red dot, seropositive.

335   **Tables**

336   **Table 1.** Study participant demographics

Characteristics	Number of participants	Proportion
Gender		
Male	236	47%
Female	264	53%
Age		
20-29	209	42%
30-39	170	34%
40-49	86	17%
50-59	28	6%
60+	7	1
Occupation		
Clinical HCW	331	66%
Non-Clinical HCW	169	34%
COVID-19 work		
Clinical	205	41%
Non-Clinical	43	9%
None	252	50%
Transport		
Public + Walking	363	73%
Private	137	27%

339   **COVID-19, Coronavirus Diseases of 2019; HCW, Health Care Workers**

345
346
347

348 **Table 2.** Crude estimates of predicted mortality at the observed seroprevalence
349

Age	Population* (Blantyre)	Population* (Malawi)	Infection fatality rate †	Number of Infections		Deaths	
				Blantyre	Malawi	Blantyre	Malawi
0-9 yrs	207,002	5,394,769	0.00%	24,840	663,557	0	11
10-19 yrs	199,915	4,753,846	0.01%	23,990	584,723	2	41
20-29 yrs	176,360	2,997,379	0.03%	21,163	368,678	7	114
30-39 yrs	130,362	2,160,103	0.08%	15,643	265,693	13	224
40-49 yrs	67,618	1,316,593	0.16%	8,114	161,941	13	261
50-59 yrs	28,397	722,800	0.60%	3,408	88,904	20	529
60-69 yrs	15,225	494,678	1.93%	1,827	60,845	35	1,174
70-79 yrs	5,715	280,394	4.28%	686	34,488	29	1,476
80+ yrs	2,001	152,762	7.80%	240	18,790	19	1,466
Total	**832,595**	**18,273,324**		**99,911**	**2,247,619**	**138**	**5,295**

351 ***2018 Population and Housing Census. † estimates derived from Verity, R. et al. 2020.**
352 **The total number of reported COVID-19 deaths on 16th July in Blantyre was 17 and in**
353 **Malawi was 51.**
354
355

Figure 1. SARS CoV-2 serological results from asymptomatic health care workers

Figure 2. Map of Blantyre showing geospatial distribution of seropositive results